Following BC and GC, the third tumor type that HER2+ is UC, while the expression level of HER2 in patients was 48% with overexpression and approximately 20% with low expression (Fleischmann et al., 2011; Yorozu et al., 2020). Here, ERBB2 is linked to neoplasm.